AUTHOR=Li Nana , Cao Ting , Wu Xiangxin , Tang Mimi , Xiang Daxiong , Cai Hualin 

TITLE=Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs

JOURNAL=Frontiers in Pharmacology

VOLUME=10

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01669

DOI=10.3389/fphar.2019.01669

ISSN=1663-9812

ABSTRACT=<p>Metabolic side effects such as weight gain and disturbed lipid metabolism are often observed in the treatment of atypical antipsychotic drugs (AAPDs), which contribute to an excessive prevalence of metabolic syndrome among schizophrenic patients. Great individual differences are observed but the underlying mechanisms are still uncertain. Research on pharmacogenomics indicates that gene polymorphisms involved in the pathways controlling food intake and lipid metabolism may play a significant role. In this review, relevant genes (<italic>HTR2C</italic>, <italic>DRD2</italic>, <italic>LEP</italic>, <italic>NPY</italic>, <italic>MC4R</italic>, <italic>BDNF</italic>, <italic>MC4R</italic>, <italic>CNR1</italic>, <italic>INSIG2</italic>, <italic>ADRA2A</italic>) and genetic polymorphisms related to metabolic side effects of AAPDs especially dyslipidemia were summarized. Apart from clinical studies, <italic>in vitro</italic> and <italic>in vivo</italic> evidence is also analyzed to support related theories. The association of central and peripheral mechanisms is emphasized, enabling the possibility of using peripheral gene expression to predict the central status. Novel methodological development of pharmacogenomics is in urgent need, so as to provide references for individualized medication and further to shed some light on the mechanisms underlying AAPD-induced lipid disturbances.</p>